Use of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 to prevent secondary hyperparathyroidism or the symptoms thereof

Abstract

Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D 3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.

We claim: 
     
       1. A method of preventing an increase in serum parathyroid levels in a subject having secondary hyperparathyroidism, the method comprising administering a therapeutically effective amount of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D 3  or pharmaceutically acceptable salts thereof to the subject without inducing hypercalcemia in the subject wherein an increase in serum parathyroid levels are prevented. 
     
     
       2. The method of  claim 1 , wherein the 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D 3  is formulated in an oral, topical, transdermal, parenteral, injection or infusion dosage form. 
     
     
       3. The method of  claim 1 , wherein the therapeutically effective amount ranges from about 1 ng/kg bw to about 10 ng/kg bw. 
     
     
       4. The method of  claim 1 , wherein the subject is receiving hemodialysis treatment. 
     
     
       5. The method of  claim 4 , wherein the subject is administered a therapeutically effective amount of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D 3  three times per week. 
     
     
       6. The method of  claim 1 , wherein the subject has renal failure. 
     
     
       7. The method of  claim 1 , wherein the subject has a glomerular filtration rate of less than 15 mL/min/1.73 m 2 .